OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies
New York, New York--(Newsfile Corp. - February 4, 2026) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give Kids A Chance Act. Mikaela, like so many other children, courageously battled pediatric cancer - specifically Osteosarcoma. Her legacy through this legislation will accelerate critical opportunities for research and therapeutic
2026-02-04 12:45 PM EST | OS Therapies
Bloom Burton & Co. Announces the 2026 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce the launch of the 2026 Bloom Burton Award and to open nomination submissions from the public at large on or before March 27, 2026. The finalists for the 2026 Bloom Burton Award will be announced at the 2026 Bloom Burton & Co. Healthcare Investor Conference, taking place at the Metro Toronto Convention Centre from April 21-22, 2026.
Technology, Biotechnology, Investment Banking, Health
2026-02-04 8:25 AM EST | Bloom Burton & Co. Inc.
Izotropic Closes Non-Brokered Private Placement and Announces Debt Settlement
British Columbia and Sacramento, California--(Newsfile Corp. - February 4, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces that further to its January 28, 2026 annou
2026-02-04 8:00 AM EST | Izotropic Corporation
Theralase(R) Provides Update on Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to provide an update on the Phase II clinical study for bladder cancer. To date, 90 patients have been enrol
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-04 7:00 AM EST | Theralase Technologies Inc.
Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, Quebec--(Newsfile Corp. - February 4, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a breakthrough intracellular delivery technology d
Biotechnology, Pharmaceuticals, Health
2026-02-04 3:15 AM EST | Defence Therapeutics Inc.
Medexus Schedules Third Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - February 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, February 12, 2026 to discuss Medexus's results for its third fiscal quarter ended December 31, 2025. Medexus expects to file its financial statements and MD&A after markets close on February 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-03 5:30 PM EST | Medexus Pharmaceuticals Inc.
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No. 2022-554855, titled "Purine Compounds for Treating Disorders
2026-02-03 4:30 PM EST | Marvel Biosciences Corp.
MustGrow's Canola Field Trials Demonstrate Clubroot Disease Suppression; Improved Canola Yield with Healthier Root Systems
MustGrow's mustard-derived organic biocontrol technology TerraMGTM focuses on soil-borne disease and pest suppression, which has been shown to improve soil conditions, crop yields, and healthier root systems; Clubroot is a soil-borne parasitic disease with devastating effects on canola production across the Canadian Prairies with no effective products currently registered for Clubroot suppression; Fi
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-02-03 10:37 AM EST | MustGrow Biologics Corp.
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, dilated cardiomyopathy, and vascular dementia, in Florida, Canada, The Bahamas, is pleased to announce the appointment of Dr. York Hsiang as a Business Consultant. "Since 2006, the first question I have
Biotechnology, Pharmaceuticals, Health
2026-02-03 8:55 AM EST | Hemostemix Inc.
Case Reports in Regrowth Announces Publication of Muhammad Qasim Observational Case Report and Invites Medical Review
New York, New York--(Newsfile Corp. - February 3, 2026) - Case Reports in Regrowth today announced the publication of an observational case report documenting late-onset hair regrowth and related physical observations in a 49-year-old male subject, Muhammad Qasim. The published case report presents a structured, non-clinical record compiled over an extended observation period. The documentation includes longitudinal v
2026-02-03 4:43 AM EST | Case Reports in Regrowth
Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates t
2026-02-02 12:10 PM EST | Sharp Therapeutics Corp.
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a specialty pharmaceutical company, today announced a new strategic initiative to pursue Health Canada approval for generic semaglutide in Canada and, subject to regulatory approval, its commercialization. Semaglutide is the active ingredient in Ozempic® and Wegovy®. The initiative builds on PharmaTher's demonstrated regulatory and partnering e
Biotechnology, Pharmaceuticals
2026-02-02 9:27 AM EST | PharmaTher Holdings Ltd.
Theralase(R) Completes Enrollment in Bladder Cancer Clinical Study
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of light, radiation, sound and/or drug-activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it has successfully co
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-02 7:00 AM EST | Theralase Technologies Inc.
Aires Enters Collaboration Agreement with Leading Wellness Expert Gary Brecka's Brand, The Ultimate Human
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) ("Aires" or the "Company"), a pioneer in advanced technology designed to transform electromagnetic field (EMF) environments to support health and well-being, entered a Collaboration Agreement (the "Agreement") with the Ultimate Human, LLC, the legal entity behind influencer Gary Brecka's wellness brand, The Ultimate
2026-02-02 6:00 AM EST | American Aires Inc.
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Request for FDA Rolling Review submitted to FDA on January 30, 2026 Non-Clinical and CMC BLA modules submitted to FDA At FDA's request, Type D Meeting expected in March 2026 to review Comparative Oncology biomarker data from patients treated in OST-HER2 Phase 2b human clinical trial and OST-HER2 trial in spontaneous osteosarcoma in canines Final BLA clinical module expected to be submitted to FDA by end of March 2026 after Type D Mee
2026-02-02 6:00 AM EST | OS Therapies
TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered into a strategic media partnership with Dr. Phil and Envoy Media, providing access to an audience of over 19 million monthly viewers which marks a significant step in acc
Technology, Biotechnology, Pharmaceuticals, Health
2026-02-02 3:00 AM EST | TempraMed Technologies Ltd
Telo Genomics Announces Appointment of John Price as Chief Financial Officer
Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately. Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has
2026-01-29 8:00 AM EST | Telo Genomics Corp.
Nextleaf Reports Fiscal Year 2025 Financial Performance
Vancouver, British Columbia--(Newsfile Corp. - January 28, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to report its financial results for the Fiscal Year (FY) 2025. For the twelve months ended September 30, 2025, the Company delivered a transformative performance, including a dramatic reduction in net loss, increased gross profit, a
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-01-28 4:30 PM EST | Nextleaf Solutions Ltd.
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnology, Pharmaceuticals, Health
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation